Siemens Encourages Involvement - Raise Awareness for Breast Cancer
After a highly successful campaign in October 2010, Siemens is continuing its commitment to promoting the early detection of breast cancer. Siemens has launched a new campaign with the motto "Turn your city pink! Raise awareness for breast cancer". The company is encouraging people around the world to spread the campaign motto in their personal environments in the most creative and public ways possible. The color pink is a global symbol of solidarity with breast cancer patients. Participants should document their efforts - in which pink should be a prominently featured color - in photos or a video and upload them to the campaign website.
Read more ...
Boost for Personalised Oral Drug Delivery as IntelliCap gains CE Mark
IntelliCap, the unique personalised oral drug delivery and monitoring system pioneered by biotech innovator Medimetrics, has gained CE approval for its use in a clinical setting. This follows the successful completion of rigorous clinical testing and validation to confirm its effectiveness and safety. The IntelliCap capsule is given orally. It passes through the digestive tract as a result of natural gut movement (peristalsis, for example). It is unique in the way it controls the release of a drug, giving precisely the right dosage, at the right place and time within the gastro-intestinal tract.
Read more ...
Bio-Images and Medimetrics Partner to Deliver the Next Generation of Smart Pill Technology
Bio-Images Research and Medimetrics Personalized Drug Delivery have today announced a partnership to introduce the IntelliCap to the global pharmaceutical industry as a clinical research tool. Medimetrics' IntelliCap is the first device that allows patient specific drug delivery by combining electronically controlled drug delivery with patient monitoring and real-time communication/interaction with the patient.
Read more ...
clin360 Set to Change the Medical Research Study Game Permanently
The days of slow, disorganized clinical trials and isolated silos of information are finally over. clin360 is a new content management system (CMS) for the
healthcare market that will forever change the way we carry out and even think about clinical trials. The pharmaceutical industry, research organizations, and healthcare professionals alike are sure to appreciate the convenience and flexibility of this ingenious platform, which acts as a central hub for sites, doctors, CRAs, and anybody else involved - or even merely interested - in any particular trial. And more importantly, vital clinical trials involving potentially life-saving technology will proceed on a more timely basis.
Read more ...
Next generation allergy vaccines to be developed in Finland
VTT Ventures Oy has established a spin-off which develops next generation allergy vaccines. The spin-off is called Desentum Oy, and its operations are based on a VTT patented technology. Years of research, testing and official approval cycles are still required before the vaccines are ready for launch. VTT holds patents on gene technology which can be applied to alter the structure of an allergen, i.e. a protein causing allergy, so that it will cause less allergic symptoms than the original allergen, while remaining effective in desensitisation therapy.
Read more ...
Teva to use INFOTEHNA myPharmaExpert Suite as a global solution
Teva Pharmaceutical Industries Ltd. has approved INFOTEHNA's myPharmaExpertTM Suite in Teva Portfolio as a global solution. In next 15 months INFOTEHNA's solution will be rolled out to thousands of users in more than 10 global sites. Teva is the global leader in generic pharmaceuticals and a leading global supplier of active pharmaceutical ingredients (API), operating in 60 countries with 42,000 employees worldwide and the largest product portfolio in the industry.
Read more ...
Scientists discover 3 new gene faults which could increase melanoma risk by 30 percent
An international team of researchers has discovered the first DNA faults linked to melanoma - the deadliest skin cancer - that are not related to hair, skin or eye colour. Cancer Research UK scientists at the University of Leeds, together with a team from the GenoMEL consortium*, scanned the genes in blood samples from almost 3000 Europeans with melanoma, and compared these with samples taken from the general population. Their findings are published in Nature Genetics.**
Read more ...